Mesoblast Limited (MESO) has completed its first year since launching its lead product, Ryoncil, and has reached nearly $100 million in revenue.
In December 2024, the FDA approved Mesoblast's Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older. It is the first FDA-approved mesenchymal stromal cell (MSC) therapy.
On March 27 2025, Mesoblast announced the launch of RYONCIL for purchase in the United States.
Now, for the quarter ended March 31, 2026, the firm reported net sales of $30.3 million, compared with $30 million in the previous quarter ended December 31, 2025.
The firm noted that January sales were low due to holidays, but strong sales in February and March made up for it.
Mesoblast develops allogeneic off-the-shelf cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
Mesoblast is currently evaluating Ryoncil in a pivotal trial as part of a second-line regimen for adults with SR-aGvHD, a market approximately three times the size of the pediatric market, according to Mesoblast.
MESO has traded between $9.66 and $21.50 in the last year. The stock closed Monday's trade at $14.7, up 0.41%.
For More Such Biotech and Pharmaceutical News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.